top
    Home
    Registration
    Accommodation
    Invitation Letter
    Contact Us
     Home
     Welcome Note
     Congress Chairpersons
     Scientific Committee
     Faculty
     Scientific Program
     Timetable
     CME
     Young Investigators Posters
         Submission Guidelines
         Poster Presentation Guidelines
         Award Ceremony
         Poster Texts
     Registration
         Invitation Letter
     Sponsors
     Sponsorship & Exhibition
     Accommodation
         Hotel Rey Juan Carlos
         Hotel Senator Barcelona
     General Information
         Before you travel...
         Transportation
         Italian Agent
         Tips and Hints
     About Barcelona
     Partners
  
1st World Congress on
Controversies in the Management of Viral Hepatitis (C-Hep)
Palau de Congressos de Catalunya, Barcelona, Spain, 19-22 May, 2011
 
  Michael P. Manns Print
 

Michael P. Manns, MD


Curriculum vitae
1970 – 1976 Medical School, University of Vienna, Austria, and Johannes-Gutenberg-University, Mainz, Germany
1976   Doctor of Medicine
1977  Licence as MD
1977-1981 Resident and Fellow, Department of Internal Medicine, Klinikum Charlottenburg, Free University of Berlin, Berlin, Germany
1981-1985 Resident and Fellow, Department of Medicine I, University of Mainz, Germany
1984  Licence for Internal Medicine
1985-1991 Staff Physician (Oberarzt), Department of Medicine I, University of Mainz; Germany
1985  Subspecialist for Gastroenterology and Hepatology
1986  Professor of Medicine and Gastroenterology, University of Mainz
1987-1988 Research Associate – W.M. Keck Autoimmune Disease Centre, Scripps Clinic and Research Foundation, Dept. of Basic and Clinical Research, La Jolla, CA, USA
1989-1991 Staff Physician (Oberarzt), Department of Medicine I, University of Mainz; Germany
since 1991 Chairman, Department of Gastroenterology, Hepatology and Endocrinology, Center of Internal Medicine, Medical School of Hannover (MHH)
1997-1999 Medical Director, MHH
1997-2003  Chairman, Sonderforschungsbereich 265 (collaborative project) of DFG  on Pathophysiology and Immune Reactions after Organ Transplantation
since 1998   Member, Scientific Advisory Board, Robert Koch Institute, Berlin
since 1998  Member, Advisory Board, University Hospital Erlangen, Germany
1999-2001 Member, Senate of Hannover Medical School
and 2009 - 
since 2002 Founder and Chairman of Hep-Net, national network of competence on viral hepatitis
2004   Founder of DFG Clinical Research Group on Hepatocellular Carcinoma (KF0 119)
since 2004  Advisory Board, University Hospital Magdeburg 
2005-2009   Chairman, Center of Internal Medicine, Medical School of Hannover
2005 - 2009 Steering committee member of VIRGIL, EU network of excellence on viral resistence in flue and viral hepatitis
since 2006  Founder, German Liver Foundation
2006  President, German Society of Gastroenterology (DGVS)
since 2006   Member, Steering Committee of REBIRTH, DFG Cluster of Excellence on Regenerative Medicine 
2007  Chairman, DFG Sonderforschungs-bereich 738 “Optimizing conventional and innovative transplants“ (collaborative project)
since 2008  Member, Steering Committee of BMBF-IFB, integrated center for research and treatment in transplantation medicine
since 2009  Member, Advisory Board, University Hospital Mainz
since 2009 Member, committee on coordination of University Medicine, Munich
since 2010  Vice Chairman, Transregio-SFB 77, “Liver Cancer”
since 2010  Member, committee on medical structure, Baden-Württemberg
since 2011  Member, selection committee, Alexander von Humboldt Foundation, Bonn , Germany

Activities in the scientific community, honors, awards
1985  Boehringer Ingelheim Award of the University of Mainz, Germany
1990  NATO Collaboration Research Award, Brussels, Belgium
1990  Clinical Research Award, GSK Foundation, Göttingen
1991  Clemens van Pirquet Award,
University of California Davis, USA
1991  Ralph Wright Memorial Lecture, British Association for the Study of the Liver, London, UK
1993  Sheila Sherlock State of the Art Lecture, Int. Association for the Study of the Liver, Cancun, Mexico
1993  Third  British Liver Trust Lecture
1995  International Hans Popper Award
Basel, Switzerland
1997  Sir Michael Perrin Lecture, Royal College of Physicians, London, UK
2000  Leon Schiff State-of-the-Art Lecture, American Association for the Study of the Liver, Dallas, USA
2002  Dr. Robert-Pfleger-Award, Bamberg, Germany (German Academy of Science)
2002  Member, Deutsche Akademie der Naturforscher Leopoldina, National Academy of Science,  Halle, Germany
2003  Max-Siurala-Award, Finish Society of Gastroenterology, Turku, Finland
2004  Member, Academy of Science,  Göttingen
2007       EASL Recognition Award, Barcelona, Spain
2008   Sheila Sherlock State-of-the-Art Lecture, British Society of Gastroenterology, Birmingham, UK
2008  Most cited European author in Gastroenterology and Hepatology (1996 – 2006) (www.lab-times.org)
2009         Hippokrates Award, Hellenic Society of Internal Medicine, Athens
2010            Resnick Lecturer and Visiting Professor, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA  

Research fields
• inflammatory liver diseases, viral and autoimmune
• clinical trials for the treatment of liver diseases, in particular viral hepatitis, autoimmune liver diseases, liver transplantation
• recurrent disease after liver transplantation
• hepatocellular carcinoma
• gastrointestinal oncology
• cell therapy: hepatocyte transplantation
• regenerative medicine
• mucosal immunology 
• clinical pharmacology
Selected publications
Manns MP, Meyer zum Bueschenfelde KH. A mitochondrial antigen-antibody system in cholestatic liver disease detected by radioimmunoassay. Hepatology 1982; 2: 1-7.
Manns MP, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Büschenfelde KH. Characterization of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. The Lancet 1987;i:292-294.
Manns MP, Johnson EF, Griffin KJ, Tan EM, Sullivan KF. The major antigen of liver-kidney-microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450 db1. J Clin Invest 1989; 83:1066-1079.
Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1autoantibodies recognize a short linear sequence in P4502D6, a cytochrome P450 monooxygenase. J Clin Invest 1991;88(4):1370-1378.
Michel G, Ritter A, Gerken G, Meyer zum Bueschenfelde KH, Decker R, Manns MP. Anti- GOR and hepatitis C virus in autoimmune liver diseaes. The Lancet 1992; 339: 267-9.
Philipp T, Durazzo M, Trautwein C, Alex B, Straub P, Lamb G, Johnson EF, Tukey RH, Manns MP. Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D. The Lancet 1994;344:578-581.
Desmet V, Gerber MA, Hoofnagle JH, Manns MP, Scheuer P. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-20. 
Takaki, Wiese M, Maertens G,Depla E, Seifert U, Liebetrau A, Miller JL, Manns MP, Rehermann B. Cellular immune responses persist, humoral responses decline two decades after recovery from a single source outbreak of hepatits C. Nat Med 2000;6:578-582.
Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein C, Manns MP; German Acute Hepatitis C Gherapy Group. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001 Nov 15;345(20):1452-1457.
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. The Lancet. 2001;358:958-65.
Tillmann HL, Heiken H, Knapik-Botor A, Heringlake S, Ockenga J, Wilber JC, Georgen B, Detmer J, McMorrow M, Stoll M, Schmidt RE, Manns MP. Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med 2001;345:715-724.
Zender L, Hütker S, Liedke C, Tillmann HL, Zender S, Mundt B, Waltemathe M, Gösling T, Flemming P, Malek NP, Trautwein C, Manns MP, Kühnel F, Kubicka S. Caspase 8 siRNA prevents acute liver failure in mice. Proc Natl Acad Sci USA 2003;100:7797-802.
Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, Kauffmann W, Kallinowski B, Cornberg M, Jaeckel E, Wedemeyer H, Manns MP; German HEP-NET Acute HCV Study Group. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 2006, 43(2):250-6.
Kossatz U, Vervoorts J, Nickeleit I, Sundberg HA, Arthur JS, Manns MP, Malek NP. C-terminal phosphorylation controls the stability and function of p27kip1. EMBO J 25:5159-5170 (2006)
Timmerbeul I, Garrett-Engele CM, Kossatz U, Chen X, Firpo E, Grünwald V, Kamino K, Wilkens L, Lehmann U, Buer J, Geffers R, Kubicka S, Manns MP, Porter PL, Roberts JM, Malek NP. Testing the importance of p27 degradation by the SCFskp2 pathway in murine models of lung and colon cancer. Proc Natl Acad Sci USA 103: 14009-14014 (2006)
Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M. The way forward in HCV treatment—finding the right path. Nat Rev Drug Discov 6(12):991-1000 (2007)
Holdener M, Hintermann E, Bayer M, Rhode A, Rodrigo E, Hintereder G, Johnson EF, Gonzalez FJ, Pfeilschifter J, Manns MP, Herrath MG, Christen U. Braking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med ;205:1409-22 (2008)
Marcellin P, Heathcote EJ, Buti M, Gane E, de Man     RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med;359:2442-55 (2008)
Manns MP Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM. AASLD Practice Guidelines: Diagnosis and Management of Autoimmune Hepatitis. Hepatology 51: 2193-2213 (2010)
MCHutchison JG, Manns MP, Muir AJ, Terrault NA,Jacobson IM, Afdahl NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, DiBisceglie AM and the PROVE 3 Study Team. Telaprevir combined with Peginterferon and ribavirin in Hepatitis C patients who have not had a sustainedVirologic response to initial interferon-based therapy. N Engl J Med, 362: 1292 – 303 (2010)
Manns MP, Woynarkowski M, Kreisel W, Lurie Y, Rust C, Zuckerman E, Bahr MJ, Gunther R, Hultcrantz RW, Spengler U, Lohse AW, Szalay F, Farkkila M, Proels M, Strassburg CP. Azathioprine with budesonide induces remission more effectively than with prednisone in patients with autoimmune hepatitis. Gastroenterology; 139: 1198-1206 (2010).
Wedemeyer H, Yurdaydin C, Dalekos G, Ehrhardt A, Cakaloglu Y, Degertekin K, Gurel S, Zeuzem S, Zachou K, Bozkaya H, Bock CT, Dienes H, Manns MP. Peginterferon plus Adefovir versus either drug alone for hepatitis delta. New Engl J Med, 364: 322 – 331, 2011

 

Home    Contact Us   
 
Copyright © 2007 comtecmed.com. All rights reserved.   The website was last updated on 10/16/2011 Created by     WebStudio.co.il